Nektar Therapeutics sell The Goldman Sachs Group, Inc.
Start price
28.02.23
/
50%
€1.32
Target price
28.02.24
€1.88
Performance (%)
-50.72%
End price
29.02.24
€0.65
Summary
This prediction ended on 29.02.24 with a price of €0.65. The_Goldman_Sachs_Gr correctly predicted massive losses of -50.72% for Nektar Therapeutics. The_Goldman_Sachs_Gr has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | 19.121% | 19.121% | 113.723% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $3.00 to $2.00. They now have a "sell" rating on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten